Company intelligence / Profile preview

Molecular Targeted Radiopharmaceuticals Holding

Waldburg, Baden-Württemberg, Germanyde.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Molecular Targeted Radiopharmaceuticals is an early-stage company developing a new class of radiopharmaceutical agents for both diagnosis and treatment of solid tumors. The company leverages the overexpression of specific tumor antigens to deliver targeted radiation. As of now, its programs are in pre-clinical development and no clinical results have been reported publicly[2][9].

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Beyond the preview

Go deeper on Molecular Targeted Radiopharmaceuticals Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Targeted Radiopharmaceuticals Holding.

Explore the full profile